Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:28165452  

DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis.

Nirit Mor-Vaknin | Anjan Saha | Maureen Legendre | Carmelo Carmona-Rivera | M Asif Amin | Bradley J Rabquer | Marta J Gonzales-Hernandez | Julie Jorns | Smriti Mohan | Srilakshmi Yalavarthi | Dave A Pai | Kristine Angevine | Shelley J Almburg | Jason S Knight | Barbara S Adams | Alisa E Koch | David A Fox | David R Engelke | Mariana J Kaplan | David M Markovitz
Nature communications | 2017

Novel therapeutics are required for improving the management of chronic inflammatory diseases. Aptamers are single-stranded RNA or DNA molecules that have recently shown utility in a clinical setting, as they can specifically neutralize biomedically relevant proteins, particularly cell surface and extracellular proteins. The nuclear chromatin protein DEK is a secreted chemoattractant that is abundant in the synovia of patients with juvenile idiopathic arthritis (JIA). Here, we show that DEK is crucial to the development of arthritis in mouse models, thus making it an appropriate target for aptamer-based therapy. Genetic depletion of DEK or treatment with DEK-targeted aptamers significantly reduces joint inflammation in vivo and greatly impairs the ability of neutrophils to form neutrophil extracellular traps (NETs). DEK is detected in spontaneously forming NETs from JIA patient synovial neutrophils, and DEK-targeted aptamers reduce NET formation. DEK is thus key to joint inflammation, and anti-DEK aptamers hold promise for the treatment of JIA and other types of arthritis.

Pubmed ID: 28165452

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIAID NIH HHS, United States
    Id: R01 AI062248
  • Agency: NIAMS NIH HHS, United States
    Id: K01 AR055620
  • Agency: NIAMS NIH HHS, United States
    Id: R03 AR056748
  • Agency: NIAMS NIH HHS, United States
    Id: T32 AR007080
  • Agency: NHLBI NIH HHS, United States
    Id: F32 HL094017
  • Agency: NCI NIH HHS, United States
    Id: P30 CA046592
  • Agency: NCI NIH HHS, United States
    Id: F31 CA150523
  • Agency: NIGMS NIH HHS, United States
    Id: T32 GM007863
  • Agency: NIAMS NIH HHS, United States
    Id: R01 AR038477
  • Agency: NIAMS NIH HHS, United States
    Id: K08 AR066569
  • Agency: NIAID NIH HHS, United States
    Id: UM1 AI110557
  • Agency: NIAMS NIH HHS, United States
    Id: R03 AR052482
  • Agency: NCI NIH HHS, United States
    Id: F30 CA210379
  • Agency: NIGMS NIH HHS, United States
    Id: T32 GM007544
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK109188

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


GE Healthcare (tool)

RRID:SCR_000004

A commercial antibody supplier and provider of various services.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions